医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Acelity Launches PREVENA PLUS™ Incision Management System with Customizable Dressing for a Range of Complex Procedures

2016年09月07日 PM11:00
このエントリーをはてなブックマークに追加


 

SAN ANTONIO

Acelity, a global wound care and regenerative medicine company, today announced the expansion of its PREVENA™ Therapy portfolio with the global launch of the PREVENA PLUS™ Incision Management System. The PREVENA PLUS™ System offers the proven effectiveness of closed incision negative pressure therapy (ciNPT) with improved versatility, portability, and flexibility. PREVENA™ Therapy helps hold incision edges together and protects incisions from external infectious sources, and the new PREVENA PLUS™ System, now available in the United States and various global markets, includes a Customizable Dressing designed for linear, non-linear, and intersecting incisions up to 90cm in length.

“Surgical site infections present a serious and costly challenge during post-operative recovery, with more than 8 million people at risk each year in the US alone,” said Devinder Singh, M.D., Chief and Medical Director of Plastic Surgery at Anne Arundel Medical Center, Annapolis, Maryland. “This risk is increased by factors such as anatomical location or incision length. The PREVENA PLUS™ Incision Management System provides an important tool for clinicians to provide negative pressure therapy to these more complex incisions.”

The PREVENA PLUS™ Incision Management System is designed specifically for the management of surgical incisions that continue to drain following sutured or stapled closure. The System enables clinicians to manage incisions up to 90 cm in length with an adjustable dressing, and allows a surgeon to apply PREVENA™ Therapy following a number of procedures including laparotomy, panniculectomy, spinal fusion, revision hip and knee arthroplasty and lower extremity trauma fracture. It uses a foam bolster to provide negative pressure at -125mmHg for up to seven days and patented SENSAT.R.A.C™ Technology that monitors and maintains pressure at the incision site. It includes a replaceable 150ml canister to keep exudates away from the incision site.

“At Acelity, our focus is always on improving patients’ lives and creating economic value by addressing post-operative complications that can affect recovery and create enormous cost burdens to the overall healthcare system,” said Joe Woody, president and chief executive officer of Acelity. “The addition of the PREVENA PLUS™ Incision Management System provides clinicians with new options for surgical patients backed by the Acelity technology and service they have come to trust.”

PREVENA™ Therapy covers and protects incisions from external contamination, while negative pressure removes fluid and infectious material from the site. PREVENA™ Therapy Systems are optimized for patient safety with visual and audible alarms and ionic silver within the interface layer designed to reduce bacterial colonization in the fabric.

About Acelity

Acelity L.P. Inc. and its subsidiaries are a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management IP Co B.V. Available in more than 80 countries, the innovative and complementary ACELITY™ product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,800 people around the world.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160907006061/en/

CONTACT

Acelity
Kathryn Skeen, +1-210-882-2067
Corporate Communications
kathryn.skeen@acelity.com
or
Caleb
Moore, +1-210-255-6433
Investor Relations
caleb.moore@acelity.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究